stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) EPS (diluted)
Ascendis Pharma A/S's EPS (diluted) for fiscal 2025 was −$4.25, compared with −$7.07 in fiscal 2024. Over the twelve months to 30 June 2026 it was $12.89. Over the past ten years it has ranged from −$10.96 (fiscal 2022) to −$1.54 (fiscal 2015); the current reading is higher than 73% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Ascendis Pharma A/S ranks 11th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$4.25 | — |
| FY2024 | −$7.07 | — |
| FY2023 | −$9.24 | — |
| FY2022 | −$10.96 | — |
| FY2021 | −$8.28 | — |
| FY2020 | −$9.46 | — |
| FY2019 | −$5.25 | — |
| FY2018 | −$3.74 | — |
| FY2017 | −$4.33 | — |
| FY2016 | −$2.85 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $3.29 | (71.17%) |
| Mar 2026 | $11.41 | — |
| Dec 2025 | −$0.64 | — |
| Sep 2025 | −$1.17 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ASND Ascendis Pharma A/S | $12.89 |
| HALO Halozyme Therapeutics, Inc. compare | $3.93 |
| EXEL Exelixis, Inc. compare | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| INSM Insmed, Inc. compare | −$2.82 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ASND
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement